{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:02:11Z","timestamp":1761897731896},"reference-count":51,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2022.15720","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T15:00:53Z","timestamp":1654614053000},"page":"e2215720","source":"Crossref","is-referenced-by-count":4,"title":["Association of High-Deductible Health Plan Enrollment With Spending on and Use of Lenalidomide Therapy Among Commercially Insured Patients With Multiple Myeloma"],"prefix":"10.1001","volume":"5","author":[{"given":"Shelley A.","family":"Jazowski","sequence":"first","affiliation":[{"name":"Department of Health Policy and Management, UNC (University of North Carolina at Chapel Hill) Gillings School of Global Public Health"},{"name":"Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacie B.","family":"Dusetzina","sequence":"additional","affiliation":[{"name":"Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee"},{"name":"Vanderbilt-Ingram Cancer Center, Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Yousuf","family":"Zafar","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina"},{"name":"Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina"},{"name":"Sanford School of Public Policy, Duke University, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah L.","family":"Zullig","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina"},{"name":"Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"issue":"11","key":"zoi220460r1","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1200\/JCO.2017.75.2501","article-title":"Breast cancer diagnosis and treatment after high-deductible insurance enrollment.","volume":"36","author":"Wharam","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi220460r2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10549-018-4821-z","article-title":"Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer.","volume":"171","author":"Lu","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"zoi220460r6","first-page":"741","article-title":"Impact of consumer-directed health plans on low-value healthcare.","volume":"23","author":"Reid","year":"2017","journal-title":"Am J Manag Care"},{"issue":"3","key":"zoi220460r7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1377\/hlthaff.2018.05026","article-title":"Vulnerable and less vulnerable women in high-deductible health plans experienced delayed breast cancer care.","volume":"38","author":"Wharam","year":"2019","journal-title":"Health Aff (Millwood)"},{"issue":"2","key":"zoi220460r8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10549-018-4819-6","article-title":"Total and out-of-pocket expenditures among women with metastatic breast cancer in low-deductible versus high-deductible health plans.","volume":"171","author":"Leopold","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"zoi220460r9","doi-asserted-by":"publisher","first-page":"e957","DOI":"10.1200\/JOP.18.00699","article-title":"High-deductible health plans and cancer survivorship: what is the association with access to care and hospital emergency department use?","volume":"15","author":"Zheng","year":"2019","journal-title":"J Oncol Pract"},{"issue":"7","key":"zoi220460r10","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.jval.2019.01.015","article-title":"Cancer history, health insurance coverage, and cost-related medication nonadherence and medication cost-coping strategies in the United States.","volume":"22","author":"Zhao","year":"2019","journal-title":"Value Health"},{"issue":"6","key":"zoi220460r11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.8965","article-title":"Association between high-deductible health plans and disparities in access to care among cancer survivors.","volume":"3","author":"Cole","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"12","key":"zoi220460r12","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1080\/17474086.2019.1682545","article-title":"What are the implications of cost for myeloma therapy?","volume":"12","author":"Xu","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"zoi220460r13","first-page":"204","article-title":"Estimating the costs of therapy in patients with relapsed and\/or refractory multiple myeloma: a model framework.","volume":"8","author":"Roy","year":"2015","journal-title":"Am Health Drug Benefits"},{"issue":"6","key":"zoi220460r14","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1185\/03007995.2015.1031732","article-title":"Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.","volume":"31","author":"Arikian","year":"2015","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"zoi220460r15","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/jnci\/djz243","article-title":"Oral oncology parity laws, medication use, and out-of-pocket spending for patients with blood cancers.","volume":"112","author":"Dusetzina","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"zoi220460r16","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1200\/EDBK_200867","article-title":"Value and cost of myeloma therapy.","volume":"38","author":"Rajkumar","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"zoi220460r17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple myeloma: diagnosis and treatment.","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"zoi220460r18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1586\/14737140.2015.1033407","article-title":"Lenalidomide in multiple myeloma.","volume":"15","author":"Kim","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"zoi220460r19","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.mayocp.2017.01.003","article-title":"Therapy for relapsed multiple myeloma: guidelines from the Mayo stratification for myeloma and risk-adapted therapy.","volume":"92","author":"Dingli","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"zoi220460r21","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","article-title":"Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.","volume":"32","author":"Dusetzina","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi220460r22","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1200\/JCO.2017.74.5091","article-title":"Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents.","volume":"36","author":"Doshi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7-8","key":"zoi220460r23","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1345\/aph.1H018","article-title":"Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures.","volume":"40","author":"Hess","year":"2006","journal-title":"Ann Pharmacother"},{"issue":"7","key":"zoi220460r24","doi-asserted-by":"publisher","first-page":"801","DOI":"10.18553\/jmcp.2016.22.7.801","article-title":"The influence of a community pharmacy automatic prescription refill program on Medicare Part D adherence metrics.","volume":"22","author":"Lester","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"issue":"8","key":"zoi220460r25","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.annepidem.2007.03.011","article-title":"A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients.","volume":"17","author":"Klabunde","year":"2007","journal-title":"Ann Epidemiol"},{"issue":"7","key":"zoi220460r26","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/aje\/kwh090","article-title":"A modified Poisson regression approach to prospective studies with binary data.","volume":"159","author":"Zou","year":"2004","journal-title":"Am J Epidemiol"},{"issue":"3","key":"zoi220460r27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/pds.v29.3","article-title":"Opening the black box of the group-based trajectory modeling process to analyze medication adherence patterns: an example using real-world statin adherence data.","volume":"29","author":"Hickson","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"zoi220460r28","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/pds.v25.8","article-title":"The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer.","volume":"25","author":"Winn","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"zoi220460r29","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/MLR.0b013e3182984c1f","article-title":"Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence.","volume":"51","author":"Franklin","year":"2013","journal-title":"Med Care"},{"issue":"3","key":"zoi220460r30","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s10549-020-05549-x","article-title":"Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.","volume":"180","author":"Lambert-C\u00f4t\u00e9","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"zoi220460r31","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jama.2011.506","article-title":"Patterns of nonadherence to antiepileptic drug therapy in children with newly diagnosed epilepsy.","volume":"305","author":"Modi","year":"2011","journal-title":"JAMA"},{"issue":"6","key":"zoi220460r32","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/cpt.v103.6","article-title":"Group-based trajectory models: assessing adherence to antihypertensive medication in older adults in community pharmacy setting.","volume":"103","author":"Dillon","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"zoi220460r33","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/pds.v28.11","article-title":"Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia.","volume":"28","author":"Cole","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"zoi220460r34","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1377\/hlthaff.2020.00714","article-title":"Annual out-of-pocket spending clusters within short time intervals: implications for health care affordability.","volume":"40","author":"Chen","year":"2021","journal-title":"Health Aff (Millwood)"},{"issue":"10","key":"zoi220460r37","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1377\/hlthaff.2014.0497","article-title":"Specialty drug coupons lower out-of-pocket costs and may improve adherence at the risk of increasing premiums.","volume":"33","author":"Starner","year":"2014","journal-title":"Health Aff (Millwood)"},{"issue":"7","key":"zoi220460r38","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.11014","article-title":"Use of health savings accounts among US adults enrolled in high-deductible health plans.","volume":"3","author":"Kullgren","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"6","key":"zoi220460r39","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/pon.v25.6","article-title":"Identifying cancer patients who alter care or lifestyle due to treatment-related financial distress.","volume":"25","author":"Nipp","year":"2016","journal-title":"Psychooncology"},{"issue":"5","key":"zoi220460r40","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1002\/cam4.v10.5","article-title":"Comparison of efficacy, safety, patients\u2019 quality of life, and doctors\u2019 occupational stress between lenalidomide-based and bortezomib-based induction in patients with newly diagnosed multiple myeloma.","volume":"10","author":"Xu","year":"2021","journal-title":"Cancer Med"},{"issue":"3","key":"zoi220460r41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0214446","article-title":"Adherence to immunomodulatory drugs in patients with multiple myeloma.","volume":"14","author":"Cransac","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"zoi220460r43","doi-asserted-by":"publisher","first-page":"186","DOI":"10.18553\/jmcp.2020.26.2.186","article-title":"Medication adherence, health care utilization, and costs among patients initiating oral oncolytics for multiple myeloma or chronic lymphocytic leukemia\/small lymphocytic lymphoma.","volume":"26","author":"Dashputre","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"zoi220460r45","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1200\/EDBK_238527","article-title":"Induction therapy for newly diagnosed multiple myeloma.","volume":"39","author":"Paul","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"zoi220460r46","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/annonc\/mdt509","article-title":"Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents.","volume":"25","author":"Merz","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"zoi220460r47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jgo.2019.05.014","article-title":"Autologous stem cell transplant in older patients (age =65) with newly diagnosed multiple myeloma: a systematic review and meta-analysis.","volume":"11","author":"Mian","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"20","key":"zoi220460r49","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1001\/jama.2019.4492","article-title":"Specialty drug pricing and out-of-pocket spending on orally administered anticancer drugs in Medicare Part D, 2010 to 2019.","volume":"321","author":"Dusetzina","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"zoi220460r51","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1377\/hlthaff.2021.01742","article-title":"Many Medicare beneficiaries do not fill high-price specialty drug prescriptions.","volume":"41","author":"Dusetzina","year":"2022","journal-title":"Health Aff (Millwood)"},{"key":"zoi220460r3","volume-title":"The Kaiser Family Foundation Employer Health Benefits 2019 Annual Survey","author":"Claxton","year":"2019"},{"key":"zoi220460r4","unstructured":"Daly? R. Enrollment of large-company workers in high-deductible plans reaches a historic high. Healthcare Financial Management Association. August 14, 2019. Accessed November 9, 2021. https:\/\/www.hfma.org\/topics\/news\/2019\/08\/enrollment-of-large-company-workers-in-high-deductible-plans-rea.html"},{"key":"zoi220460r5","unstructured":"Catranach J. High-deductible health plans continue to grow in popularity, but are they right for you? ValuePenguin. Updated January 24, 2022. Accessed November 9, 2021. https:\/\/www.valuepenguin.com\/high-deductible-health-plan-study"},{"key":"zoi220460r20","unstructured":"McAuliff? M. Sky-high drug prices driven by pharma profits, House Dems charge. Kaiser Health News. September 30, 2020. Accessed November 9, 2021. https:\/\/khn.org\/news\/sky-high-drug-prices-driven-by-pharma-profits-house-dems-charge\/"},{"key":"zoi220460r35","unstructured":"Shafer? P, Horny? M, Dusetzina? SB. Rethinking annual deductibles: the case for monthly cost-sharing limits. Health Affairs Blog. October 16, 2020. Accessed November 9, 2021. https:\/\/www.healthaffairs.org\/do\/10.1377\/forefront.20201013.566424\/full"},{"key":"zoi220460r36","unstructured":"Internal Revenue Service. Additional preventive care benefits permitted to be provided by a high deductible health plan under \u00a7223. 2019. Notice 2019-45. Accessed November 30, 2021. https:\/\/www.irs.gov\/pub\/irs-drop\/n-19-45.pdf"},{"key":"zoi220460r42","unstructured":"Sweiss? K. Oral antimyeloma therapy: barriers to patient adherence and tips for improvement. Hematology\/Oncology Pharmacy Association. 2018;15(3). Accessed November 9, 2021. https:\/\/www.hoparx.org\/hopa-news\/volume-15-issue-3-2018\/oral-antimyeloma-therapy-barriers-to-patient-adherence-and-tips-for-improvement"},{"key":"zoi220460r44","unstructured":"Hansen? LA. Best practices in maximizing adherence to cancer therapy. The Oncology Pharmacist. April 27, 2020. Accessed November 9, 2021. https:\/\/www.theoncologypharmacist.com:443\/ton-online-first\/3695-ton-3695"},{"key":"zoi220460r48","unstructured":"Watson Health. IBM MarketScan Research Databases for life sciences researchers. July 2021. Accessed November 9, 2021. https:\/\/www.ibm.com\/downloads\/cas\/OWZWJ0QO"},{"key":"zoi220460r50","unstructured":"Revlimid. US prescribing information. Celgene Corporation; 2021. Accessed March 29, 2022. https:\/\/packageinserts.bms.com\/pi\/pi_revlimid.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2793104\/jazowski_2022_oi_220460_1654005906.23115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T15:01:00Z","timestamp":1654614060000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2793104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.15720","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,7]]}}}